Literature DB >> 9163845

Significance of elevated procollagen-III-peptide and transforming growth factor-beta levels of bronchoalveolar lavage fluids from idiopathic pulmonary fibrosis patients.

N Hiwatari1, S Shimura, K Yamauchi, M Nara, W Hida, K Shirato.   

Abstract

Although both procollagen III aminopeptide (P-III-P) and transforming growth factor-beta (TGF-beta) are reported to be present in lung tissue and/or elevated in bronchoalveolar lavage fluid (BALF) from idiopathic pulmonary fibrosis (IPF) patients, we have little knowledge concerning the clinical significance of elevated P-III-P and TGF-beta levels in BALF. Using a radioimmunoassay, we measured P-III-P and TGF-beta in BALF from 48 IPF patients (16F and 32M, 59 +/- 2 years, mean +/- S.E.) who received BAL in our clinic over the past 13 years before glucocorticosteroid treatment. Among them, we could detect a significant amount of P-III-P (2.2 +/- 1.0 U/ml; range 0.03 to 16.5 U/ml) in BALF in 18 of the patients (5F and 13M, 58 +/- 3 years) (group B). but not (0.03 U/ml or less) in the other 30 patients (11F and 19M, 59 +/- 2 years) (group A). Lymphocyte (%) and basophil (%) in BALF from group B was much larger than that from group A (33% vs. 8%, p < 0.01). Group B showed a longer duration of onset to BAL (36 months vs. 23 months, p < 0.05). TGF-beta levels were obtained using an ELISA system kit from the same BALF samples. TGF-beta was not detected in 10 patients (100 pg/ml or less) (3F and 7M, 59 +/- 4 years) (group I), while the remaining 38 patients showed a significant amount of TGF-beta (329 +/- 44 pg/ml, range 100 to 1,360 pg/ml). The latter patients were further divided into two groups; group II 100 to 300 pg/ml (10F and 14M, 56 +/- 3 years) and group III 350 or more (3F and 11M, 63 +/- 2 years). Group III showed significantly better values in PaO2, Aa-DO2, %VC and %DLco, and smaller percentage of basophils in BALF than did groups I and/or II, whereas survival after BAL in group III was significantly shorter than in group I (31 vs. 19 months, p < 0.05). There was no significant relationship between P-III-P and TGF-beta levels in BALF. These findings suggest that elevated P-III-P level is accompanied by an increase in lymphocyte population in BALF from IPF patients, resulting in a longer duration of the disease, while elevated TGF-beta level reflects alveolar inflammation at an earlier stage of the disease which induces a progression of the disease, resulting in a shorter survival in IPF patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163845     DOI: 10.1620/tjem.181.285

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  9 in total

1.  Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis.

Authors:  Anna P Lam; Jose D Herazo-Maya; Joseph A Sennello; Annette S Flozak; Susan Russell; Gökhan M Mutlu; G R Scott Budinger; Ramanuj DasGupta; John Varga; Naftali Kaminski; Cara J Gottardi
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

2.  Transforming growth factor β suppresses glutamate-cysteine ligase gene expression and induces oxidative stress in a lung fibrosis model.

Authors:  Rui-Ming Liu; Praveen Kumar Vayalil; Carol Ballinger; Dale A Dickinson; Wen-Tan Huang; Suqing Wang; Terrance J Kavanagh; Qiana L Matthews; Edward M Postlethwait
Journal:  Free Radic Biol Med       Date:  2012-05-23       Impact factor: 7.376

3.  Mutant surfactant A2 proteins associated with familial pulmonary fibrosis and lung cancer induce TGF-β1 secretion.

Authors:  Meenakshi Maitra; Christopher A Cano; Christine Kim Garcia
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-05       Impact factor: 11.205

4.  Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis.

Authors:  Ragini Vittal; Amanda Fisher; Hongmei Gu; Elizabeth A Mickler; Alyssa Panitch; Cynthia Lander; Oscar W Cummings; George E Sandusky; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

5.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23

Review 6.  Interstitial fibrosis and growth factors.

Authors:  J A Lasky; A R Brody
Journal:  Environ Health Perspect       Date:  2000-08       Impact factor: 9.031

7.  Transforming growth factor beta 1 activation, storage, and signaling pathways in idiopathic pulmonary fibrosis in dogs.

Authors:  E Krafft; P Lybaert; E Roels; H P Laurila; M M Rajamäki; F Farnir; M Myllärniemi; M J Day; K Mc Entee; C Clercx
Journal:  J Vet Intern Med       Date:  2014-10-20       Impact factor: 3.333

8.  Active transforming growth factor-beta1 activates the procollagen I promoter in patients with acute lung injury.

Authors:  G R Scott Budinger; Navdeep S Chandel; Helen K Donnelly; James Eisenbart; Monica Oberoi; Manu Jain
Journal:  Intensive Care Med       Date:  2004-11-24       Impact factor: 17.440

9.  A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts.

Authors:  Elizabeth Monaghan-Benson; Erika S Wittchen; Claire M Doerschuk; Keith Burridge
Journal:  Mol Biol Cell       Date:  2018-07-11       Impact factor: 4.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.